New Patent Application for Treating P53 Mutant Cancers Using OGDH Inhibitors

Strategic Insights -

Researchers have been working on developing innovative treatments for p53 mutant cancers, a type of cancer characterized by mutations in the tumor suppressor gene TP53. A new patent application, filed by Scott E. Millman, Lydia Finley, Scott Lowe, and John P. Morris IV, proposes using OGDH inhibitors to treat or prevent p53 mutant cancers. OGDH, which stands for 2-oxoglutarate dehydrogenase, is a key enzyme involved in cellular metabolic pathways.

The patent application highlights the potential of OGDH inhibitors in treating various types of p53 mutant cancers, including pancreatic cancer and acute myeloid leukemia (AML). According to the inventors' summary, the method involves administering an effective amount of an OGDH inhibitor to a subject in need of treatment. The OGDH inhibitor may be a small molecule, a nucleic acid sequence, or an anti-OGDH neutralizing antibody. Additionally, the inventors suggest that the method may include simultaneously administering other therapeutic agents to enhance treatment efficacy.

Key Takeaways:

  • The patent application proposes using OGDH inhibitors to treat or prevent p53 mutant cancers, including pancreatic cancer and AML.
  • The OGDH inhibitor may be a small molecule, a nucleic acid sequence, or an anti-OGDH neutralizing antibody.
  • The method involves administering the OGDH inhibitor to a subject in need of treatment, with the option to add other therapeutic agents to enhance treatment efficacy.
  • The inventors highlight the potential of OGDH inhibitors in treating p53 mutant cancers, a type of cancer characterized by mutations in the TP53 gene.
  • The patent application notes that the OGDH inhibitor may be used to treat various types of cancers, including liver cancer and AML.

Statistics:

  • AML impacts approximately 20,000 new cases and 11,000 deaths each year in the United States (Source: National Cancer Institute).
  • Acute myeloid leukemia (AML) accounts for 25% of pediatric leukemia but more than half of childhood leukemia deaths (Source: National Cancer Institute).
  • The 5-year survival rate for pediatric AML is one of the worst among childhood cancers, with only a 5-15% cure rate for those diagnosed before the age of 60 (Source: National Cancer Institute).
  • Complex karyotype AML, defined as leukemia harboring three or more chromosomal abnormalities, portends a particularly unfavorable prognosis, with overall survival at 5 years at less than 20% (Source: Finley et al., patent application).

Sources:

  • Finley, L., Lowe, S., Millman, S. E., & Morris, J. P. (2020). Methods of treating p53 mutant cancers using Ogdh inhibitors. Filed August 13, 2020. Patent URL: https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220220280538%22.PGNR.&OS=DN/20220280538&RS=DN/20220280538
  • National Cancer Institute. (2022). Acute Myeloid Leukemia (AML). Retrieved from https://www.cancer.gov/types/myeloid/patient/myeloid-treatments-pdq#section/_203
  • National Cancer Institute. (2022). Childhood Cancer Rates. Retrieved from https://www.cancer.gov/types/childhood-cancer/rates-fact-sheet